Clinical trials investigating crizotinib alone [ClinicalTrials.gov:NCT 02101385 (Schneider 2016)] or in combination with anti-VEGF therapy [ClinicalTrials.gov:NCT 02074878 (Baylor Breast Care Center 2015)] for the treatment of advanced triple negative breast cancer are currently underway. The gene discussed is VEGFA; the disease is triple-negative breast carcinoma.